ClinicalTrials.gg
Active, not recruitingNCT07857031EXIT-CVDUpdated Oct 5, 2026

EXIT-CVD Project: Evidence Based Exit Strategies for the Cardiovascular Disease Continuum Trough Early Detection, Treatment and Evaluation

An interventional study of Photon Counting Computed Tomography (PCCT) in CAD - Coronary Artery Disease, sponsored by Centro Cardiologico Monzino. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.

Sponsored by Centro Cardiologico Monzino · Not applicable, Interventional, and Diagnostic

How we know

Updated Oct 5, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino — 4 open to participants now, 6 under way, none of them phase 3. Coronary Artery Disease · Centro Cardiologico Monzino.

Started
2026
with 1 other
No phase
5 of 11
1 open now
Registered
10th of 11
by date

Among the 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino, this one is one of 2 that started in 2026, is one of 5 with no phase, and was the 10th registered.

Coronary Artery Disease

4,866 studies on the registry are indexed under Coronary Artery Disease; 892 are open to participants now.

Browse Coronary Artery Disease studies →

Open to participants now

4 of the 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 591 Coronary Artery Disease studies recruiting now, 404 (68%) set no upper age limit and 68 (12%) stop at 75 or younger; 37 take children under 18; 49 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Coronary Artery Disease by Centro Cardiologico Monzino, or all of them as a file.
02

Study summary

This prospective, single-center interventional imaging study aims to evaluate the diagnostic performance of Photon Counting Computed Tomography (PCCT) combined with artificial intelligence-based Quantitative Coronary CT (AI-QCT) analysis in patients with suspected or known coronary artery disease (CAD).

Read the detailed description

Adult patients with a positive conventional coronary CT angiography (CCTA) who are scheduled for clinically indicated invasive coronary angiography with intravascular ultrasound (IVUS) will undergo an additional PCCT acquisition for research purposes. PCCT datasets will be analyzed using a dedicated post-processing platform implementing artificial intelligence-based Quantitative Coronary CT (AI-QCT) algorithms for automated plaque quantification and characterization, including assessment of plaque burden, plaque composition, stenosis severity, and high risk plaque features. Conventional CCTA and PCCT images will be compared within the same patient to assess image quality, coronary stenosis, plaque burden and composition, high-risk plaque features, CAD-RADS classification, radiation exposure, and contrast medium volume.

Invasive coronary angiography and IVUS findings will serve as reference standards to evaluate the diagnostic accuracy and agreement of CT-derived measurements. The study will assess whether PCCT combined with AI-QCT provides improved coronary plaque characterization, diagnostic performance, and cardiovascular risk stratification compared with conventional CCTA, while potentially reducing radiation exposure and contrast medium requirements.

03

Conditions studied

  • CAD - Coronary Artery Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults (≥ 18 years)
  • Patients with suspected or known CAD and a positive conventional coronary CT angiography requiring further invasive evaluation.
  • Patients scheduled for clinically indicated invasive coronary angiography with IVUS assessment.
  • Ability to under go an additional PCCT scan according to the study protocol
  • Ability and willingness to provide written .

Exclusion criteria

Exclusion Criteria:

  • to CT imaging or iodinated contrast media
  • Severe renal impairment ( \<30 mL/min/1.73 m²)
  • Pregnancy or breastfeeding.
  • Hemodynamic instability or inability to undergo CT acquisition
  • Significant arrhythmias impairing image acquisition quality.
  • Inability to provide .
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    PCCT and AI-QCT Imaging

    Participants with suspected or known coronary artery disease and a positive conventional coronary CT angiography (CCTA) will undergo an additional Photon Counting Computed Tomography (PCCT) acquisition for research purposes. PCCT images will be analyzed using a dedicated image post-processing platform incorporating artificial intelligence-based Quantitative Coronary CT (AI-QCT) algorithms for the assessment of coronary stenosis, plaque burden, plaque composition, and high-risk plaque features. PCCT findings will be compared with conventional CCTA findings and with invasive coronary angiography and intravascular ultrasound (IVUS), which will serve as reference standards.

    Radiation: Photon Counting Computed Tomography (PCCT)

Interventions

  • RadiationPhoton Counting Computed Tomography (PCCT)

    Participants will undergo an additional Photon Counting Computed Tomography (PCCT) coronary angiography acquisition for research purposes after a clinically performed conventional coronary CT angiography. The PCCT examination will be performed using an optimized low-dose acquisition protocol. PCCT images will be analyzed using a dedicated image post-processing platform incorporating artificial intelligence-based Quantitative Coronary CT (AI-QCT) algorithms for quantitative and qualitative assessment of coronary artery disease, including coronary stenosis, plaque burden, plaque composition, and high-risk plaque features. Image quality, radiation exposure, and contrast medium volume will also be assessed.

06

What researchers measure

Primary outcomes

  1. Diagnostic performance of PCCT combined with AI-QCT compared with conventional CCTA

    Diagnostic performance of PCCT combined with AI-QCT for the detection and assessment of coronary artery disease, compared with conventional CCTA.

    Time frame: 16 months

Secondary outcomes

  1. Signal-to-noise ratio (SNR)

    Signal-to-noise ratio measured on conventional CCTA and PCCT images

    Time frame: 16 months

  2. Quantitative and qualitative coronary plaque characteristics measured by AI-QCT

    Plaque burden, plaque composition, and high-risk plaque features measured by AI-QCT on conventional CCTA and PCCT images.

    Time frame: 16 months

  3. Radiation dose associated with conventional CCTA and PCCT

    Radiation dose recorded for conventional CCTA and PCCT acquisitions.

    Time frame: 16 months

  4. CAD-RADS classification

    CAD-RADS classification assigned to conventional CCTA and PCCT datasets.

    Time frame: 16 months

  5. Agreement between AI-QCT and IVUS measurements of coronary plaque

    Agreement between non-invasive AI-QCT-derived measurements and corresponding invasive IVUS measurements of coronary plaque, assessed using intraclass correlation coefficient (ICC).

    Time frame: 16 months

  6. Incremental value of PCCT for cardiovascular risk stratification

    Evaluation of the incremental value of PCCT combined with AI-QCT compared with conventional CCTA for cardiovascular risk stratification and clinical decision making.

    Time frame: 16 months

  7. Contrast-to-noise ratio (CNR)

    Contrast-to-noise ratio measured on conventional CCTA and PCCT images.

    Time frame: 16 months

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Jan 2028, 16 months after the start.

Of 756 non-industry interventional studies with no phase under Coronary Artery Disease, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 53. This study's planned 16 months is below that.

Counting every sponsor, half of 933 studies reached it within 30 months; a quarter within 15 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2026
First posted
Oct 5, 2026
StartActual
Sep 1, 2026
Primary completionEst.
Jan 1, 2028
CompletionEst.
Jan 1, 2028
Last update
Oct 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 5, 2026
Show all 1 update
  1. Oct 5, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07857031
Lead sponsor
Centro Cardiologico Monzino
Responsible party
Sponsor
First posted
Oct 5, 2026
Start date
Sep 1, 2026
Primary completion
Jan 1, 2028 (estimated)
Completion
Jan 1, 2028 (estimated)
Last update
Oct 5, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion